In T2DM subjects with NASH, tirzepatide (1–15 mg/week for 26 weeks) effectively reduced ALT, AST, cytokeratin 18, Pro-C3, and increased adiponectin levels [123]. Here, GPT is linked to type 2 diabetes mellitus.